相关实验视频

Updated: Jun 14, 2025

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Published on: March 21, 2021

在开始治疗赛马格卢提德 (葡萄糖类-1受体激动剂) 后,CT基体构成的患者内变化

Leslie W Nelson¹, Matthew H Lee¹, John W Garrett^1,2,3

¹Department of Radiology, University of Wisconsin School of Medicine and Public Health, E3/311 Clinical Science Center, 600 Highland Ave, Madison, WI 53792-3252.

AJR. American journal of roentgenology

|September 4, 2024

概括

在患有2型糖尿病或肥胖的成年人中,塞马格卢提德的使用导致那些减肥的人的身体组成发生了有利的变化,包括内脏脂肪组织 (VAT) 和皮下脂肪组织 (SAT) 的减少. 体重增加与增加的VAT,SAT和肌肉间脂肪组织 (IMAT) 有关.

科学领域:

放射学和成像学放射学和成像学
内分泌学和新陈代谢学
人工智能在医学中的应用

背景情况:

作为一种类似于葡萄糖的-1受体激动剂的塞马格卢提德 (semaglutide) 是用于2型糖尿病和肥胖症的药物.
临床研究表明,塞马格卢提德在促进减肥,改善血糖控制和降低心血管风险方面具有有效性.
身体组成的变化是代谢健康和治疗反应的关键指标.

研究的目的:

评估在开始服用西马格卢提德后患者体内的身体组成变化.
利用人工智能 (AI) 驱动的计算机断层扫描 (CT) 工具进行精确的身体组成分析.

主要方法:

对241名成年患者进行了回顾性分析,这些患者接受了塞马格卢提德治疗.
腹腔皮层CT扫描在塞马格卢提德开始 (2016-2023) 之前和之后获得.
基于AI的CT分析量化了内脏脂肪组织 (VAT),皮下脂肪组织 (SAT),骨肌面积和衰减,肌际脂肪组织 (IMAT),肝体积/衰减和骨矿物质密度 (BMD).

主要成果:

减肥组 (n=67) 显示了VAT,SAT,肌肉面积和肝脏体积的显著减少,同时增加了semaglutide后的肝脏衰减.
体重增加组 (n=48) 在VAT,SAT和IMAT显著增加,肌肉衰减减少,表明肌肉质量下降.
在减肥和体重增加队列之间观察到明显的身体组成变化模式.

结论:

塞马格卢提德治疗与明显的患者体内组成变化有关,以体重变化区分开来.
在西马格卢提德治疗期间减肥与心脏代谢风险标志物的有利转变有关.
人工智能驱动的CT分析提供了有价值的生物标志物,用于评估超越标准临床指标的身体组成变化.

关键词:

这就是为什么CTCTCTCTCTCT 人工智能的人工智能是人工智能.糖尿病糖尿病患者糖尿病患者葡萄糖类-1受体激动剂.塞马格卢提德 (semaglutide) 是一种可怕的药物.

更多相关视频

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Published on: November 22, 2024

相关概念视频

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...